Topical Corticosteroid Adrenal Suppression Risk Precludes OTC Use, Advisory Committe Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Topical corticosteroid HPA axis suppression risk under "maximal use conditions" should preclude the OTC marketing of the dermatologic products, FDA advisory committees say. Test for hypothalamus, pituitary, adrenal axis suppression is only 70% accurate, committee members note.